ライフサイエンスコーパス: multiple drug resistance

1 quisition of mutations in the development of multiple drug resistance.

2 sing candidate for treatment of cancers with multiple drug resistance.

3 nt transformation and conferring tumors with multiple drug resistance.

4 is, angiogenesis, response to infection, and multiple drug resistance.

5 and paclitaxel in the context of tumors with multiple drug resistance.

6 in the PDR1-101 transcription factor confers multiple drug resistance.

7 of cancer stem-like cells (CSC) that exhibit multiple drug resistance.

8 idermal growth factor receptor (EGFR), human multiple drug resistance 1 (MDR-1) and human proliferati

9 ase chain reaction (RT-PCR) amplification of multiple drug resistance 1 (MDR1) mRNA from high prolife

10 M1 is a substrate for P-glycoprotein and the multiple drug resistance 2 transporter.

11 Rapid development of multiple drug resistance against current therapies is a

12 ew antimicrotubule compound that circumvents multiple drug resistance and so may be useful in the tre

13 mosomal genes implicated in cell physiology, multiple drug resistance and virulence.

14 recombination could contribute to high-level multiple-drug resistance and that this process must be c

15 Multiple drug-resistance bacteria (MDRB) infection is on

16 Multiple drug resistance due to P-glycoprotein (P-gp) ex

17 omology with components of fimbrial operons, multiple drug resistance efflux pumps and a haemolysin.

18 It harbors multiple drug-resistance elements including a truncated

19 r drug accumulation, or amplification of the multiple drug resistance gene (MDR).

20 rmal growth factor receptor (EGFR) and human multiple drug resistance gene (MDR-1).

21 drugs used for selection in combination with multiple drug resistance gene 1 (MDR1) could have an enh

22 ith an amphotropic retrovirus containing the multiple drug resistance gene leads to gene transfer not

23 wo plasmids, R1 and RP4, both of which carry multiple drug resistance genes and were shown to impose

24 n region V of CMV pol can, therefore, confer multiple drug resistance in a clinical isolate.

25 B operon is a regulatory locus that controls multiple drug resistance in Escherichia coli.

26 Prospective analysis of the role of multiple drug resistance in localized osteosarcoma did n

27 lle called vault, and has been implicated in multiple drug resistance in many cancer cell lines and p

28 nal infections may play an important role in multiple drug resistance in Mycobacterium avium infectio

29 lyzed prospectively to determine the role of multiple drug resistance in osteosarcoma.

30 ments often involve sequential selection for multiple-drug resistance in single ES cell lines, we hav

31 n of the gene ABCB1 (also known as MDR1, for multiple drug resistance) in HeLa cells.

32 CT18 harbours a 218,150-bp multiple-drug-resistance incH1 plasmid (pHCM1), and a 10

33 Multiple drug-resistance interpretation algorithms have

34 centration was reversed by agents that block multiple drug resistance (MDR) and by the UIC2 anti-Pgp

35 Multiple drug resistance (MDR) as a result of overexpres

36 The murine multiple drug resistance (mdr) gene, mdr1a, encodes a 17

37 to enhance therapeutic efficacy by silencing multiple drug resistance (MDR) genes and resensitizing r

38 In a search for improved multiple drug resistance (MDR) modulators, we identified

39 sterone's ability to inhibit the activity of multiple drug resistance (MDR) P-glycoproteins.

40 pression of P-glycoprotein (P-gp) can confer multiple drug resistance (MDR) phenotype on cancer cells

41 therapeutic small interfering RNA (siRNA) to multiple drug resistance (MDR) tumors.

42 transplantation were related to CYP3AP1 and multiple drug resistance (MDR)-1 genotypes determined by

43 n, which codes for the Vibrio cholerae VceAB multiple-drug resistance (MDR) efflux pump, and vceR, wh

44 MATE transporters also mediate multiple-drug resistance (MDR) in bacteria and mammals,

45 Although poorly understood, in common with multiple-drug resistance (MDR) in tumors, MHR is associa

46 The multiple-drug resistance (MDR) transporter P-glycoprotei

47 safety and efficacy of transfer of the human multiple drug resistance (MDR1, MDR) gene into hematopoi

48 many standard cytotoxic agents by means of a multiple drug resistance mechanism, remained quite susce

49 However, multiple drug resistance mechanisms can still emerge.

50 explore the hypothesis that the existence of multiple drug resistance mechanisms in different patient

51 r the taxanes in their ability to circumvent multiple drug resistance mechanisms.

52 lop resistance through stepwise selection of multiple drug-resistance mechanisms.

53 All patients failing therapy showed multiple drug resistance mutations in different compartm

54 d reverse transcriptase sequences containing multiple drug resistance mutations, amplified from patie

55 nt viruses and performed linkage analysis of multiple-drug resistance mutations.

56 nd that activates the ATPase activity of the multiple drug resistance P-glycoprotein, activated the m

57 of the MDR1 gene has been implicated in the multiple drug resistance phenotype expressed by many can

58 extrusion mechanisms including expression of multiple drug resistance proteins.

59 in the proportion of T cells expressing the multiple-drug resistance pump P-glycoprotein.

60 any neurological diseases, and the resulting multiple drug resistance represents a major clinical cha

61 her, our results support the hypothesis that multiple drug resistance to AEDs involves cerebrovascula

62 PB) cells, genetically marked with the human multiple drug resistance transgene (MDR1) were used for

63 The ATPase activity of the multiple drug resistance transporter Mdr1 (P-glycoprotei

64 le CT18 carries two plasmids, one conferring multiple drug resistance, Ty2 has no plasmids and is sen